February 7, 2014 – OncoMed Pharmaceuticals, Inc. [OMED], a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will visit the NASDAQ MarketSite in Times Square. In honor of the occasion, Paul J. Hastings, Chairman & CEO, will ring the Closing Bell.
Paul is a 1984 Alum of the College of Pharmacy and has been the committed supporter of the College and the University since he graduated. In 2012 he was honored at the 13th Annual Diversity Awards.